The product is indicated to reduce chronic severe drooling in children aged 3 to 16 years old with neurologic conditions that cause too much (abnormal) drooling.
[Read more: Par intros generic Chantix]
"We're proud to provide families with a generic option of this important medication," said Jon Holden, senior vice president and general manager, generics at Endo. "Glycopyrrolate oral solution joins our extensive portfolio of high-quality, lower-cost generic products—and our reputation for dependable quality is an especially essential factor when treating children."
Cuvposa had a market value of approximately $27 million for the 12 months ended Oct. 31, 2021, according to IQVIA.
[Read more: Par launches authorized generic of Amitiza]